Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,157 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Imaging agent Clear all
Recruiting Phase 2 Interventional

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

NCT07087860
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
Other · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 1, 2026, 10:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation

NCT02791568
View directory record Official record
Conditions
Pregnancy, Obesity, Preeclampsia
Interventions
Ultrasound Scan, MRI Scan, Ferumoxytol
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 1, 2026, 10:13 PM EDT
Completed Phase 1 Interventional

11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

NCT03424525
View directory record Official record
Conditions
Bacterial Infections
Interventions
11C-Trimethoprim
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 1, 2026, 10:13 PM EDT
Recruiting Early Phase 1 Interventional

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

NCT03861676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal brachytherapy with PSMA PET imaging, (18F)DCFPyL
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 1, 2026, 10:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

TumorGlow Intraoperative Molecular Imaging (IMI)

NCT04723810
View directory record Official record
Conditions
Tumor, Solid
Interventions
Indocyanine Green
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 1, 2026, 10:13 PM EDT
Completed Early Phase 1 Interventional Results available

A Microdose Evaluation Study of ABY-029 in Recurrent Glioma

NCT02901925
View directory record Official record
Conditions
Glioma
Interventions
ABY-029
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 1, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Imaging of Lidoderm for Chronic Back Pain

NCT01515540
View directory record Official record
Conditions
Low Back Pain
Interventions
lidocaine, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 1, 2026, 10:13 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

NCT04234568
View directory record Official record
Conditions
Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor
Interventions
Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Triapine
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 1, 2026, 10:13 PM EDT
Terminated Phase 4 Interventional Results available

Natalizumab and Chronic Inflammation

NCT05177718
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Natalizumab 300 MG in 15 ML Injection
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 1, 2026, 10:13 PM EDT
Recruiting Phase 3 Interventional

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07217717
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
[18F]FAPI-74 PET/CT
Drug
Lead sponsor
SOFIE
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Cerritos, California • Duarte, California • Irvine, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 1, 2026, 10:13 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

NCT02913131
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pyruvate (13C), MRI
Drug · Device
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 1, 2026, 10:13 PM EDT
Completed Phase 1 Interventional

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

NCT01303705
View directory record Official record
Conditions
Metastatic Prostate Cancer, Cancer of the Prostate, Prostate Cancer
Interventions
Anti-OX40, Radiation, Cyclophosphamide
Drug · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 1, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

NCT05635045
View directory record Official record
Conditions
Transthyretin Amyloidosis
Interventions
I 124-Evuzamitide
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 105 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 1, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Safety and Efficacy Study of IS-001 Injection in Patients Undergoing Robotic Hysterectomy

NCT03937505
View directory record Official record
Conditions
Ureter Injury
Interventions
IS-001, No treatment
Drug
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Austin, Texas • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 1, 2026, 10:13 PM EDT
Completed No phase listed Observational

Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System

NCT02690805
View directory record Official record
Conditions
Breast Cancer
Interventions
MR-compatible scinti-mammography (MRI-SMM) system
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 1, 2026, 10:13 PM EDT
Recruiting Phase 4 Interventional

Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors

NCT04265430
View directory record Official record
Conditions
Malignant Oral Cavity Neoplasm, Malignant Skull Base Neoplasm, Osteoradionecrosis
Interventions
Contrast Agent, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 1, 2026, 10:13 PM EDT
Recruiting Phase 2 Interventional

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

NCT07462507
View directory record Official record
Conditions
Central Nervous System Cancer, Brain Metastases
Interventions
[C-11]-CS1P1, Brain MRI
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 1, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets

NCT04950166
View directory record Official record
Conditions
Peritoneal Carcinomatosis
Interventions
pegsitacianine
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Winston-Salem, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 1, 2026, 10:13 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Clinical PRoduct DevelOpment StudyinG the QT Ultrasound® BReast ScannEr With Volunteer SubjectS

NCT02948361
View directory record Official record
Conditions
Volunteer Subjects
Interventions
QT Ultrasound Breast Scan
Other
Lead sponsor
QT Ultrasound LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 1, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Clinical Impact of Cardiac Photon-Counting Detector CT

NCT05240807
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Photon-counting detector computed tomography (PCD-CT)
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 1, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance

NCT00926536
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
C-arm CT + DSA as needed, DSA only
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 1, 2026, 10:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Endoprosthesis Metal Toxicity Study

NCT04755140
View directory record Official record
Conditions
Bone Tumor, Cancer of Bone, Heart Diseases, Cognitive Impairment, Cognitive Decline, Chemotherapy Effect, Memory Problem
Interventions
Questionnaires, Interviews, Blood Test, Echocardiogram
Behavioral · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 1, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

NCT02237235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
MMFS-202-302, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 1, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

FMISO PET Study of Glioblastoma

NCT02076152
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
FMISO PET, MRI, Bevacizumab, CCNU
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 1, 2026, 10:13 PM EDT